The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study†

ASN002 is an oral dual inhibitor of Janus kinase and spleen tyrosine kinase, which are involved in the pathogenesis of atopic dermatitis (AD) through their regulatory role on T helper (Th)1, Th2 and Th17/Th22 pathways.

• Publication year

  2019

• Venue

  British Journal of Dermatology

• Publication date

  2019-05-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/bjd.17932PMID 30919407PMCID 6850605
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Early‐onset pediatric atopic dermatitis is characterized by TH2/TH17/TH22‐centered inflammation and lipid alterations

  2018cited by this paper
• Atopic dermatitis: a review of topical nonsteroid therapy

  2018cited by this paper
• A novel JAK inhibitor JTE‐052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: Comparison with conventional therapeutic agents

  2018cited by this paper
• JAK inhibitors appear to have a bright future in the treatment of atopic dermatitis

  2018cited by this paper
• JAK Inhibitors for Atopic Dermatitis: An Update

  2018cited by this paper
• Baricitinib in adult patients with moderate‐to‐severe atopic dermatitis: A phase 2 parallel, double‐blinded, randomized placebo‐controlled multiple‐dose study

  2018cited by this paper
• Atopic dermatitis in diverse racial and ethnic groups—Variations in epidemiology, genetics, clinical presentation and treatment

  2018cited by this paper
• Spleen tyrosine kinase inhibition ameliorates airway inflammation through modulation of NLRP3 inflammosome and Th17/Treg axis

  2018cited by this paper
• The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins

  2017cited by this paper
• Prolonged fasting suppresses mitochondrial NLRP3 inflammasome assembly and activation via SIRT3-mediated activation of superoxide dismutase 2

  2017cited by this paper
• Systemic therapies in atopic dermatitis: The pipeline.

  2017cited by this paper
• [Paraoxonase: The Universal Factor of Antioxidant Defense in Human Body].

  2017cited by this paper
• Use of a proximity extension assay proteomics chip to discover new biomarkers associated with albuminuria

  2017cited by this paper
• Safety and Efficacy of Phototherapy in the Management of Eczema.

  2017cited by this paper
• TLR4 signals in B lymphocytes are transduced via the B cell antigen receptor and SYK

  2017cited by this paper
• Alterations in B‐cell subsets in pediatric patients with early atopic dermatitis

  2017cited by this paper
• Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.

  2016cited by this paper
• Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli.

  2016cited by this paper
• Spleen Tyrosine Kinase Mediates EGFR Signaling to Regulate Keratinocyte Terminal Differentiation.

  2016cited by this paper
• XGR software for enhanced interpretation of genomic summary data, illustrated by application to immunological traits

  2016cited by this paper
• Atopic dermatitis

  2016cited by this paper
• Pathway analysis of expression-related SNPs on genome-wide association study of basal cell carcinoma

  2016cited by this paper
• Interferon γ-Induced Nuclear Interleukin-33 Potentiates the Release of Esophageal Epithelial Derived Cytokines

  2016cited by this paper
• Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin.

  2016cited by this paper
• MV140, a sublingual polyvalent bacterial preparation to treat recurrent urinary tract infections, licenses human dendritic cells for generating Th1, Th17, and IL-10 responses via Syk and MyD88

  2016cited by this paper
• Drug evaluation review: dupilumab in atopic dermatitis.

  2015cited by this paper
• Spleen Tyrosine Kinase Mediates EGFR Signaling to Regulate Keratinocyte Terminal Differentiation.

  2015cited by this paper
• The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization.

  2015cited by this paper
• The Reactome pathway Knowledgebase

  2015cited by this paper
• The extracellular matrix: Tools and insights for the "omics" era.

  2015cited by this paper
• Use of a proximity extension assay proteomics chip to discover new biomarkers for human atherosclerosis.

  2015cited by this paper
• Immune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted Therapeutics

  2015cited by this paper
• Gene Ontology and KEGG Pathway Enrichment Analysis of a Drug Target-Based Classification System

  2015cited by this paper
• Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents.

  2014cited by this paper
• Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity, and Excellent Scalability

  2014cited by this paper
• Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis.

  2014cited by this paper
• Guidelines of care for the management of atopic dermatitis: Section 4. Prevention of disease flares and use of adjunctive therapies and approaches.

  2014cited by this paper
• The Reactome pathway knowledgebase

  2013cited by this paper
• Signaling by IL-31 and functional consequences.

  2012cited by this paper
• An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.

  2010cited by this paper
• Spleen tyrosine kinases: biology, therapeutic targets and drugs.

  2010cited by this paper
• Therapeutic targeting of Janus kinases

  2008cited by this paper
• JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies.

  2008cited by this paper
• Nature Publishing Group

  2006cited by this paper
• The Janus protein tyrosine kinase family and its role in cytokine signaling.

  1995cited by this paper
• [Atopic dermatitis].

  1980cited by this paper

• Efficacy and safety of treatments for atopic dermatitis: a model based meta-analysis of randomized controlled trials

  2026cites this paper
• Update on Non-Biological and RNA-Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules.

  2026cites this paper
• Eczema: etiology, subtypes, therapeutic approaches and socioeconomic impact

  2026cites this paper
• Recent updates on thymic stromal lymphopoietin as a therapeutic target for asthma.

  2026cites this paper
• Novel Therapeutic Strategies for Atopic Dermatitis: Biomarker Modulation and Clinical Implications. A Systematic Review

  2026cites this paper
• Anti-Inflammatory Therapies for Atopic Dermatitis: A New Era in Targeted Treatment

  2025influential citation
• Large‐Scale Blood Proteomic Analysis Across Different Inflammatory Skin Conditions Reveals Extensive Immune Dysregulation With Distinct Biomarker Profiles

  2025cites this paper
• From Pathways to Patients in Atopic Dermatitis: Advanced Systemic Therapies

  2025cites this paper
• Recent Progress of Molecular Design and Activities of Spleen Tyrosine Kinase (SYK) Inhibitors

  2025cites this paper
• Pathophysiologic Mechanisms and Targeted Treatments Associated with the Nervous System in Cutaneous Allergic Diseases

  2025cites this paper
• Clinical and Molecular Effect of the Anti–IL‐18 Antibody Aletekitug in Adults With Atopic Dermatitis

  2025cites this paper
• SYHX1901, an oral dual JAK/SYK inhibitor, for moderate-to-severe plaque psoriasis: a randomized phase 2 trial.

  2025cites this paper
• Disease-modifying strategies: Targeting protein kinases in multiple sclerosis and other autoimmune disorders.

  2025cites this paper
• Advancements in pharmacological interventions for atopic dermatitis current strategies and future directions

  2025cites this paper
• An unbiased tissue transcriptome analysis identifies potential markers for skin phenotypes and therapeutic responses in atopic dermatitis

  2025cites this paper
• Biologic and Small Molecule Therapy for Treating Moderate to Severe Atopic Dermatitis: Mechanistic Considerations.

  2024cites this paper
• Short-Term Cardiovascular Complications in Dermatology Patients Receiving JAK-STAT Inhibitors: A Meta-Analysis of Randomized Clinical Trials.

  2024cites this paper
• Not just another klass (JAK) of inhibitors for allergies

  2024cites this paper
• Infection risk with JAK inhibitors in dermatoses: a meta‐analysis

  2024cites this paper
• Immunological Advancements In Hand Eczema Treatment: Progress With Small Molecules and Biologics

  2024cites this paper
• Treatment of Atopic Dermatitis in Children

  2024cites this paper
• An Encompassing Review on Therapeutic Targets, Therapies and Nanostructure Based Formulations for Atopic Dermatitis

  2024cites this paper
• A Practical Guide to Using Oral JAK Inhibitors for Atopic Dermatitis from the International Eczema Council.

  2024cites this paper
• Monoclonal Antibodies: Current Advancements and Future Potential for Atopic Dermatitis Therapy.

  2024cites this paper
• Current and emerging immunobiologic therapies for atopic dermatitis

  2024cites this paper
• Proteomic alterations in patients with atopic dermatitis

  2024cites this paper
• Emerging drugs for the treatment of atopic dermatitis: a focus on phase 2 and phase 3 trials

  2024cites this paper
• Prognostic and Therapeutic Potential of STAT3: Opportunities and Challenges in Targeting HPV-Mediated Cervical Carcinogenesis.

  2024cites this paper
• Emerging trends in clinical research on Janus kinase inhibitors for atopic dermatitis treatment.

  2023cites this paper
• Toward Precision Medicine in Atopic Dermatitis Using Molecular-Based Approaches

  2023cites this paper
• Diversity of Atopic Dermatitis and Selection of Immune Targets.

  2023cites this paper
• JAK Inhibitor Use for the Inpatient Dermatologist

  2023cites this paper
• Non‐biologic systemic treatments for atopic dermatitis: Current state of the art and future directions

  2023cites this paper
• Oral JAK Inhibitors for Atopic Dermatitis.

  2023cites this paper
• Topical and systemic JAK inhibitors in hand eczema – a narrative review

  2023cites this paper
• Oral SYK/JAK Inhibitor Gusacitinib for the Treatment of Chronic Hand Eczema: Results of a Randomized Phase 2 Study.

  2023cites this paper
• Janus Kinase Inhibitors in Atopic Dermatitis: New Perspectives.

  2023cites this paper
• Protein kinases: drug targets for immunological disorders

  2023cites this paper
• Challenges and Future Trends in Atopic Dermatitis

  2023cites this paper
• [[Translated article]]Janus Kinase Inhibitors in Atopic Dermatitis: New Perspectives.

  2023cites this paper
• A Review of Existing and New Treatments for the Management of Hand Eczema

  2023cites this paper
• Immunomodulatory role of spleen tyrosine kinase in chronic inflammatory and autoimmune diseases

  2023cites this paper
• Towards precision medicine in Atopic Dermatitis using molecular-based approaches

  2023cites this paper
• Systemic treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials.

  2023cites this paper
• Hand eczema: from pathogenesis to novel treatments

  2023cites this paper
• Pharmacological Insights into Janus Kinase Inhibition for the Treatment of Autoimmune Skin Diseases: A Literature Review

  2023cites this paper
• A review of biological agents and small molecules in the management of atopic dermatitis

  2023cites this paper
• The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment

  2023cites this paper
• Efficacy of topical and systemic treatments for atopic dermatitis on pruritus: A systematic literature review and meta-analysis

  2022cites this paper
• A Systematic Review of Atopic Dermatitis: The Intriguing Journey Starting from Physiopathology to Treatment, from Laboratory Bench to Bedside

  2022influential citation
• Immunotherapy in atopic dermatitis.

  2022cites this paper
• Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis

  2022cites this paper
• Racial and ethnic diversity of US participants in clinical trials for acne, atopic dermatitis, and psoriasis: a comprehensive review

  2022cites this paper
• Th2A cells: The pathogenic players in allergic diseases

  2022cites this paper
• Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases.

  2022cites this paper
• Current emerging and investigational drugs for the treatment of chronic hand eczema

  2022cites this paper
• A Literature Review of the Janus Kinase Inhibitors Used in the Treatment of Auto-Immune Dermatological Conditions

  2022cites this paper
• Polyopes affinis Suppressed IFN-γ- and TNF-α-Induced Inflammation in Human Keratinocytes via Down-Regulation of the NF-κB and STAT1 Pathways

  2022cites this paper
• JAK INHIBITORS AS A NEW MODALITY FOR TREATING ATOPIC DERMATITIS: A BETTER UNDERSTANDING OF ITS EFFICACY AND SAFETY

  2021influential citation
• Biomarkers in atopic dermatitis—a review on behalf of the International Eczema Council

  2021cites this paper
• Small molecule approaches to treat autoimmune and inflammatory diseases (Part I): kinase inhibitors.

  2021cites this paper
• Advances in the pathophysiology of atopic dermatitis revealed by novel therapeutics and clinical trials.

  2021cites this paper
• An integrated scalp and blood biomarker approach suggests the systemic nature of alopecia areata

  2021cites this paper
• Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases

  2021cites this paper
• Emerging Systemic Therapeutic Biologics and Small Molecules for Atopic Dermatitis: How to Decide Which Treatment Is Right for Your Patients.

  2021cites this paper
• Application of Janus Kinase Inhibitors in Atopic Dermatitis: An Updated Systematic Review and Meta-Analysis of Clinical Trials

  2021cites this paper
• Therapeutic New Era for Atopic Dermatitis: Part 2. Small Molecules

  2021cites this paper
• JAK inhibitors: Ten years after

  2021cites this paper
• Production of IL-31 in CD45RO+CLA+H4R+ T Cells in Atopic Dermatitis

  2021cites this paper
• Novel treatments for pediatric atopic dermatitis

  2021cites this paper
• Proteomic signatures of inflammatory skin diseases: a focus on atopic dermatitis

  2021cites this paper
• Scalp and serum profiling of frontal fibrosing alopecia reveals scalp immune and fibrosis dysregulation with no systemic involvement.

  2021cites this paper
• The IL-4, IL-13 and IL-31 pathways in atopic dermatitis

  2021cites this paper
• New Treatments for Atopic Dermatitis Targeting Skin Barrier Repair via the Regulation of FLG Expression

  2021cites this paper
• A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?

  2021cites this paper
• Early intervention and prevention of allergic diseases

  2021cites this paper
• Emerging Treatment of AD: Biologics and Small Molecules

  2021cites this paper
• Update on the Pathogenesis and Therapy of Atopic Dermatitis

  2021cites this paper
• Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial

  2021cites this paper
• The efficacy of Janus kinase inhibitors in patients with atopic dermatitis: A systematic review and network meta‐analysis

  2021cites this paper
• JAK Inhibitors in the Treatment of Atopic Dermatitis.

  2021cites this paper
• Safety considerations of systemic Janus kinase inhibitors in atopic dermatitis applications

  2021cites this paper
• Systematic Review on the Efficacy and Safety of Oral Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis

  2021cites this paper
• Janus kinase inhibitors for the therapy of atopic dermatitis

  2021cites this paper
• Efficacy and Safety of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis

  2021cites this paper
• From Emollients to Biologicals: Targeting Atopic Dermatitis

  2021cites this paper
• The JAK/STAT signaling pathway: from bench to clinic

  2021cites this paper
• Cross-sectional study of blood biomarkers of patients with moderate-to-severe alopecia areata reveals systemic immune and cardiovascular biomarker dysregulation.

  2020cites this paper
• Quoi de neuf en thérapeutique dermatologique ?

  2020cites this paper
• Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study.

  2020cites this paper
• Efficacy of biologics in atopic dermatitis

  2020cites this paper
• Biologika-Therapie der atopischen Dermatitis

  2020cites this paper
• Biological drugs in the treatment of atopic dermatitis – current recommendations of the Polish Dermatological Society, the Polish Society of Allergology, the Polish Pediatric Society and the Polish Society of Family Medicine

  2020cites this paper
• Emerging Role of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis

  2020cites this paper
• JAK-STAT Inhibitors in Atopic Dermatitis from Pathogenesis to Clinical Trials Results

  2020influential citation
• Mild atopic dermatitis lacks systemic inflammation, and shows reduced non-lesional skin abnormalities.

  2020cites this paper
• Caffeoyl-Prolyl-Histidine Amide Inhibits Fyn and Alleviates Atopic Dermatitis-Like Phenotypes via Suppression of NF-κB Activation

  2020cites this paper
• Innovation in Atopic Dermatitis: From Pathogenesis to Treatment.

  2020cites this paper
• New Treatments in Atopic Dermatitis.

  2020cites this paper
• Atopic Dermatitis – Current State of Research on Biological Treatment

  2020cites this paper